Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.
SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.
The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.
In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.
SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.
The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.
Latest News:
- March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
- March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
- March 14, 2024: First patient dosed in SCI-210 ASD trial.
- March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
- March 27, 2024: Clearmind partnership leads to multiple new patent applications.
- May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
Rhea-AI Summary
SciSparc Ltd. announces the initiation of patient recruitment for its clinical trial in Israel for SCI-210, a combination of cannabidiol (CBD) and CannAmide™, designed to alleviate symptoms of autism spectrum disorder (ASD). The goal is to commercialize SCI-210 first in Israel and then in other countries, subject to regulatory approvals. The trial aims to compare SCI-210 therapy to standard CBD treatment in managing ASD symptoms and has three primary efficacy metrics. The trial was designed in consultation with the National Autism Research Center in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.43%
Tags
-
Rhea-AI Summary
SciSparc Ltd. has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP, to purchase up to $20 million of the Company’s ordinary shares over the next thirty-six-month period. The purchase price of the ordinary shares will be at a 3% discount of the weighted average price of the Company's ordinary shares during a specific trading day period. The Company intends to use the proceeds for working capital and other general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.03%
Tags
-
Rhea-AI Summary
SciSparc Ltd. announced a bridge loan agreement with a leading vehicle importer company in Israel for the acquisition of the Target Company. The bridge loan amount is $1.4 million, with an interest rate of 7% per annum. The company intends to acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, with shareholders holding approximately 50.01% of the share capital of the resulting combined company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) reflect on a successful collaboration in 2023. Clearmind filed six provisional patent applications with the USPTO for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc. The patent applications aim to offer safer and more effective treatments for patients with mental health disorders, strengthening their IP portfolios and developing treatments that offer synergy, efficacy, and safety, while reducing the total cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.02%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) achieved a significant milestone in its joint venture with MitoCareX Bio Ltd., focusing on cancer treatment drug discovery. MitoCareX Bio successfully developed laboratory capabilities for small-molecule screening platforms, targeting human mitochondrial carriers. This achievement led to SciSparc investing an additional $600,000, resulting in a 50.1% ownership of MitoCareX Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.51%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) will acquire 100% of a leading vehicle importer company in Israel, establishing a new wholly-owned Israeli subsidiary. This follows the company's announcement in June 2022 to review potential strategic transactions to maximize shareholder value. The proposed Acquisition will result in SciSparc shareholders holding approximately 50.01% of the post-closing combined company, compared to 20% as previously announced. The Target Company's revenues for the first half of 2023 amounted to over $52 million. The Acquisition is subject to due diligence, execution of binding agreements, and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announced successful results from a pre-clinical trial for its obesity and metabolic disorder program in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The trial focused on identifying the optimal dosage for the Combination Treatment, which includes palmitoylethanolamide (PEA) and MEAI, resulting in increased metabolic activity, reduced appetite, and enhanced fat oxidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (SPRC) adopts a limited duration shareholder rights plan to protect the long-term interests of shareholders and enable them to realize the full potential value of their investment. The plan is designed to reduce the likelihood of any entity gaining control of the company without appropriately compensating all shareholders. The company's CEO, Oz Adler, emphasized the positive results from the weight loss and metabolic disorder program with a proprietary psychedelic-based treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (SPRC) announces successful results from a pre-clinical trial conducted in collaboration with Clearmind Medicine Inc. The trial focused on the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule, showing promising results for addressing obesity and related health challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
Rhea-AI Summary
SciSparc Ltd. (SPRC) announces that its joint venture, MitoCareX Bio, has achieved its second milestone by developing laboratory capabilities for cancer drug discovery. The joint venture focuses on targeting the nuclear encoded human mitochondrial carriers, with 53 members found to be altered in various malignancies. The achievement triggers an additional investment of $600,000 from SciSparc, resulting in the company holding 50.1% of MitoCareX Bio's share capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
FAQ
What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?
The current stock price of SciSparc Ltd. Ordinary Shares (SPRC) is $0.5879 as of January 23, 2025.
What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?
The market cap of SciSparc Ltd. Ordinary Shares (SPRC) is approximately 6.6M.
What does SciSparc Ltd. do?
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.
What are SciSparc's main drug development programs?
SciSparc's main programs include SCI-110 for Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for ASD and status epilepticus.
What recent achievements has SciSparc announced?
Recent achievements include enrolling the first patient in the SCI-210 ASD trial, obtaining a Canadian patent, and expanding partnerships with MitoCareX Bio and Clearmind.
What products does SciSparc offer online?
SciSparc's subsidiary sells hemp-based products like gummies, oils, capsules, and creams on Amazon Marketplace.
Where is SciSparc Ltd. based?
SciSparc Ltd. is based in Tel Aviv, Israel.
Is SciSparc involved in cancer research?
Yes, through its venture MitoCareX Bio, SciSparc is involved in cancer drug discovery targeting mitochondrial SLC25 proteins.
What patents has SciSparc recently secured?
SciSparc has recently secured patents in the U.S., Canada, and Europe for cannabinoid compositions and antimicrobial methods.
Who leads SciSparc Ltd.?
SciSparc Ltd. is led by a team of experienced senior executives and scientists.
What is SCI-210?
SCI-210 is a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for Autism Spectrum Disorder and status epilepticus.
What is the significance of SciSparc's new patents?
The new patents strengthen SciSparc's intellectual property portfolio and enhance its position in the global pharmaceutical market.
SciSparc Ltd. Ordinary Shares